On Thursday, I told you about one of my top Cyborg stocks -- Pfenex Inc (PFNX).
You've probably never heard of this company -- it's relatively small biotech with a market cap of about $400 million. But that doesn't mean it's some fly-by-night startup...
Pfenex was spun out of The Dow Chemical Company is 2009 and went public in 2015. The company primarily takes existing off-patent, generic drugs and modifies them to improve their performance. They call the new drugs, appropriately, "biosimilars."
Of course, Cyborg doesn't really care about the company does, it's how it performs that matters.
It only trades business with strong financials. It steers clear of struggling companies that aren't making money, which reduces risk and increase upside potential.
PFNX, for example, is expected to grow EPS in Q4 2019 by 130% and 450% in Q1 2020. That's a pretty outrageous growth rate, for a company of any size.
And just as impressive is how well PFNX shares have performed, they are up over 100% in the past six months and 200% in the last year.
And analysts, which are generally a pretty conservative bunch, think shares still have a ton of upside left. I agree.
But Cyborg doesn't trade one stock at a time. To reduce risk and improve performance, it enters four equally promising opportunities at the same time (you can get all my trades here).
This isn't me guessing what works best, I did extensive testing. What did it reveal? This system could have turned $1,000 into $10.6 million!
Check out some trades Cyborg pinpointed along the way:
0 Response to "You're missing three other trades..."
Post a Comment